Pressure BioSciences Expands on Recent Achievement of Major Development Milestones in Ultra Shear Technology for Diverse High Value Products, Including CBD Oil

November 28, 2018 9:05 AM

Interviewing with Proactive Investors, CEO Richard T. Schumacher Also Highlights and Accentuates Importance of Timely Appointment of Dr. Brad Young as Chief Commercial Officer SOUTH EASTON, MA / ACCESSWIRE / November 28, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life...

Read more

AzurRx BioPharma to Present at the 11th Annual LD Micro Main Event

November 28, 2018 8:00 AM

NEW YORK, NY / ACCESSWIRE / November 28, 2018 / AzurRx BioPharma, Inc. (NASDAQ: AZRX) (''AzurRx'' or the ''Company''), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced that it will be presenting at the 11th Annual LD Micro Main Event on Thursday, December 6th at 8:00 AM PST at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Thijs Spoor, Chief Executive Officer, and...

Read more

Pressure BioSciences Achieves Second Major Milestone in the Development of Its Ultra Shear Technology Platform

November 15, 2018 12:10 PM

Company Announces Successful Development of Proprietary Method for High Quality, Water Soluble Oils, Opening Major New Opportunities in Multiple Markets; Initial Focus to be in the CBD Oil and Cosmetics Markets SOUTH EASTON, MA / ACCESSWIRE / November 15, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform...

Read more

Pressure BioSciences, Inc. Reports Third Quarter and YTD 2018 Financial Results and Provides Business Update

November 14, 2018 6:30 PM

Significant Operating Loss Decrease, Initial Revenue from New Scientific Services Group, and Accelerated Development of Ultra Shear Technology Platform Highlight Q3 and YTD Results SOUTH EASON, MA / ACCESSWIRE / November 14, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life...

Read more

Neocis Inc. Reaches First Commercial Milestone for Yomi(R) - The World's First Robot-Assisted Dental Surgical System

November 14, 2018 9:45 AM

MIAMI, FL / ACCESSWIRE / November 14, 2018 / Neocis, Inc., the leader and innovator in dental implant surgery utilizing advanced robotics, announced today that it reached its first U.S. commercialization milestone with the sale of its 20th Yomi® surgical system. "Following FDA clearance, we launched the 'Pioneer Program' in the U.S. to attract early adopters. I'm extremely pleased with the commercial adoption this program received, enabling...

Read more

Pressure BioSciences, Inc. to Discuss Third Quarter 2018 Financial Results and Provide Business Update

November 14, 2018 7:11 AM

Conference Call Scheduled for Wednesday, November 14th at 4:30 PM EST SOUTH EASTON, MA / ACCESSWIRE / November 14, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its Third Quarter 2018 financial results and to provide a business update. Anyone interested may listen to the teleconference either live (by telephone) or through a replay (by telephone...

Read more

Mymetics Presents New Data Regarding Cold Chain Independent Virosome Based Vaccines

November 14, 2018 5:35 AM

EPALINGES, SWITZERLAND / ACCESSWIRE / November 14, 2018 / Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life-threatening and life disabling diseases, announces that new data is presented today by Mymetics at the annual Mucosal Vaccines, Adjuvants and Delivery meeting in Lausanne, Switzerland.Since 2015, Mymetics has been leading a consortium to develop thermostable and...

Read more

ABMC Reports Third Quarter 2018 Results

November 13, 2018 2:30 PM

KINDERHOOK, NY / ACCESSWIRE / November 13, 2018 / American Bio Medica Corporation (OTC PINK: ABMC) today announced financial results for the three and nine months ended September 30, 2018. Chief Executive Officer Melissa A. Waterhouse stated, "Although sales declined in the third quarter of 2018 when compared to the third quarter of 2017, we are still expecting new relationships/contracts to positively impact sales going forward into 2019. One...

Read more

Zivo Claims Gras Status for its Proprietary Algal Biomass, Allowing Immediate Marketing of its Premiere Product as a Human Food Ingredient

November 12, 2018 9:00 PM

KEEGO HARBOR, MI / ACCESSWIRE / November 12, 2018 / ZIVO Bioscience, Inc. (OTCMKTS: ZIVO) a biotech/agtech R&D company engaged in the commercialization of nutritional products derived from its proprietary algal strains, announces today that it has received notice from an independent scientific review panel that ZIVO has satisfied the safety and process requirements to affirm GRAS status for its proprietary Kalgae™ branded dried algal...

Read more

Pressure BioSciences Achieves Major Milestone in the Development of its Ultra Shear Technology Program

November 9, 2018 11:50 AM

Company Completes Development of First Working Prototype of UST System and Initiates Program to Develop Proprietary Method to Make Water Soluble Oils for Use in Multiple Markets SOUTH EASTON, MA / ACCESSWIRE / November 9, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide...

Read more

Dyadic International Reports Third Quarter 2018 Financial Results

November 7, 2018 4:30 PM

Initial registration statement on Form 10 filed with the SECFully funded proof of concept research collaboration signed with Sanofi-Aventis Deutschland GmbHProgress in productivity and stability in Company’s research programsJUPITER, FL / ACCESSWIRE / November 7, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to...

Read more

Qrons Enters into Placenta Sourcing Agreement under the Declaration of Helsinki

November 7, 2018 11:45 AM

Agreement Will Facilitate Completion of First Prototype Product MIAMI, FL / ACCESSWIRE / November 7, 2018 / Qrons Inc. (OTC PINK: QRON) ("Qrons" or the "Company"), a preclinical biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on treating traumatic brain injuries ("TBIs"), announced today that it has entered into an Agreement with Meir Hospital in Israel to obtain a reliable source of...

Read more

Bradford A. Young, Ph.D., MBA Joins Pressure BioSciences as Chief Commercial Officer

November 7, 2018 9:45 AM

With Academic and Industry Experience Spanning 25 Years, Dr. Young Will Combine Exceptional Industry, Business, and Marketing Skills with Strong Technical and Leadership Experience to Help Drive Product Adoption and Accelerate Revenue Growth SOUTH EASTON, MA / ACCESSWIRE / November 7, 2018 / Pressure BioSciences, Inc. (OTCQB: PBIO) (''PBI'' or the ''Company''), a leader in the development and sale of broadly enabling, pressure-based instruments,...

Read more

Molecular Partners to Present New Data on Immuno-Oncology Pipeline at Upcoming Scientific Conferences

November 6, 2018 12:36 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / November 6, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the company plans to participate in several upcoming scientific conferences in November and December 2018. At these conferences listed below, members of the Molecular Partners team will present updated research...

Read more

VTT and Dyadic International to Present Data on C1 Protein Platform at AAPS PharmSci 360 and PEGS Europe

November 5, 2018 9:45 AM

Data Demonstrate C1 Can Be Developed Into a New-Generation Therapeutic Protein Production SystemESPOO, FINLAND and JUPITER, FL / ACCESSWIRE / November 5, 2018 / VTT Technical Research Centre of Finland Ltd (''VTT'') and Dyadic International, Inc. (OTCQX: DYAI)(''Dyadic'') will present data on the companies' ongoing R&D collaboration involving Dyadic's C1 Myceliophthora thermophila fungal strain at: AAPS PharmSci 360 in Washington, DC on...

Read more

Dyadic Announces the Filing of Initial Form 10 Registration Statement with the SEC

November 5, 2018 8:30 AM

JUPITER, FL / ACCESSWIRE / November 5, 2018 / Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 expression system to help speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that the Company has filed a Form 10 registration statement with the U.S. Securities and Exchange Commission...

Read more

Neocis Names Fred Moll, M.D. to Board of Directors

November 1, 2018 1:10 PM

MIAMI, FL / ACCESSWIRE / November 1, 2018 / Neocis, Inc., an innovator in dental implant surgery utilizing advanced robotics, announced today that Fred Moll, M.D. has joined its board of directors as of September 2018. ''Fred is a respected industry leader and an ideal fit for our board,'' said Alon Mozes, PhD, Chief Executive Officer. ''His impressive career has been dedicated to revolutionizing medicine. In the field of surgical robotics, he...

Read more

Positive Phase 3 Efficacy Data for Abicipar, Ongoing Clinical Trials for MP0250 In Oncology and Further Advancement of I/O Pipeline

November 1, 2018 2:00 AM

Research & Development: MP0250 in multiple myeloma: Clinical trial ongoing with dose set at 8mg/kg every 3 weeks in combination with bortezomib/dexamethasone. Durable responses were seen in patients who came from proteasome inhibitor (PI) based pretreatment, suggesting that MP0250 might be capable of reversing PI adaptive resistance MP0250 in EGFR-mutated Non-Small Cell Lung Cancer (EGFR mut NSCLC):...

Read more

INmune Bio to Present at National Investment Banking Association Conference

October 30, 2018 8:30 AM

LA JOLLA, CA / ACCESSWIRE / October 30, 2018 / INmune Bio, Inc., a cancer immunotherapy company focused on developing therapies that harness the patient's innate immune system to attack their cancer, today announced that RJ Tesi, M.D., CEO and President of the Company, will present a company overview at the upcoming National Investment Banking Association Conference, with details as follows: National Investment Banking Association 145th...

Read more

Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic

October 29, 2018 2:00 AM

ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / October 29, 2018 / Molecular Partners AG (SWX: MOLN), a clinical-stage biopharmaceutical company pioneering the use of DARPin® therapeutics* to treat serious diseases, today announced that the phase 3 safety and efficacy data of abicipar in patients with neovascular Age-related Macular Degeneration (nAMD) were presented at the American Academy of Ophthalmology (AAO) conference in Chicago. In two...

Read more